Preoperative Dual Immunotherapy Shows Promise in High-Risk Early HER2-Negative Breast Cancer
WASHINGTON — A combination of two immunotherapy drugs produced substantially higher rates of tumor eradication when added to chemotherapy before ...
WASHINGTON — A combination of two immunotherapy drugs produced substantially higher rates of tumor eradication when added to chemotherapy before ...
Advanced triple-negative breast cancer may benefit from an unexpected combination: stereotactic ablative body radiotherapy (SABR) delivered either in a single ...
In triple-negative breast cancer (TNBC) that carries TP53 mutations, loss of one copy of the DNA ligase I gene (LIG1) ...
A groundbreaking study has unveiled new insights into the complex biology of cancer-associated fibroblasts (CAFs) within triple-negative breast cancer (TNBC), ...
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
In a groundbreaking study poised to reshape the therapeutic landscape of aggressive breast cancers, researchers have uncovered a novel metabolic ...
In a groundbreaking study published in the Journal of Translational Medicine, researchers Li, Chen, and Wang lead an exploration into ...
Triple-negative breast cancer (TNBC) remains one of the most formidable challenges in oncology due to its aggressive nature and its ...
In a groundbreaking study unveiled recently, researchers have illuminated the complex metabolic dependencies underpinning triple-negative breast cancer (TNBC), highlighting a ...
Triple-negative breast cancer (TNBC) is notorious for its aggressive nature and resistance to conventional therapies, creating an urgent need for ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine